A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin.
We have fitted a first-order multicompartment pharmacokinetic model to plasma platinum concentrations measured in nine ovarian cancer patients who received intravenous infusions of cisplatin for 6 h. The time-course of ultrafilterable plasma platinum was similar in all patients studied, and was fitted by a single compartment within the limits of experimental detection. However, the time-course of protein-bound platinum showed marked differences between patients, the differences being explained by distribution to two peripheral compartments. The wide inter-patient variation observed in protein-bound plasma platinum concentrations supports the view that pharmacokinetic modelling should be carried out separately for each patient, since averaging plasma concentrations would have obscured some individual pharmacokinetic characteristics.
Griffiths
H
H
South Wales Radiotherapy and Oncology Service, Velindre Hospital, Whitchurch, Cardiff, UK.
Shelley
M D
MD
Fish
R G
RG
D002945:Cisplatin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy; D010984:Platinum / Q000097:blood*; D011485:Protein Binding
D010984:Platinum; D002945:Cisplatin